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Abstract 
Review on PIAS1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: DDXBP1, GBP, GU/RH-II, ZMIZ3 
HGNC (Hugo): PIAS1 
Location: 15q23 
 
Chromosomal mapping of PIAS1. Modified from Weiskirchen 
et al., 2001. 
Note 
PIAS1 gene was initially located at 15q22 
(Weiskirchen et al., 2001). 
DNA/RNA 
Description 
PIAS1 gene is composed of 14 exons and spans  
 
approximately 134,8 kb of genomic DNA. 
Transcription 
PIAS1 gene encodes a 2309 bp mRNA transcript. 
Pseudogene 
No pseudogenes have been reported. 
Protein 
Description 
The human PIAS1 protein is composed of 651 amino 
acids, with a predicted molecular weight of 71,85 kDa.  
PIAS1 has five distinct functional domains, with 
different functions: the SAP (scaffold attachment 
factor-A/B, Acinus and PIAS), the PINIT motif, the 
RING-type zinc-binding domain, the SBD (SUMO 
binding domain, also indicated as SIM, SUMO 
interacting motif) and a C-terminal serine/threonine 
rich region.  
The SAP domain contains a LXXLL motif which is 
involved in direct-DNA binding or in physical 
interaction with other proteins involved in DNA-
binding, such as transcription factors, co-regulators and 
nuclear receptors (Aravind and Koonin, 2000). 
The PINIT motif is involved in the sub-cellular 
organization of PIAS1 (Duval et al., 2003).  
The RING domain is essential for the E3 SUMO-ligase 
activity of PIAS1 and also mediates protein-protein 
interactions (Hochstrasser, 2001).  
The SBD domain interact in a non-covalently way with 
SUMO proteins (Rytinki et al., 2009). 
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Structural organization of PIAS1 human gene. 
 
 
 
Schematic representation of PIAS1 protein. The different domains are illustrated. A purple square represents the SUMO binding 
domain (SBD). 
 
The C-terminal portion of PIAS1 is a serine/threonine 
rich region: this is the most variable region within the 
PIAS proteins family. PIAS1 undergoes several post-
translational modifications, including phosphorylation, 
acetylation, methylation, SUMOylation and 
ubiquitination (Liu et al., 2005; Depaux et al., 2007; 
Rytinki et al., 2009; Stehmeier and Muller, 2009; 
Weber et al., 2009). 
Expression 
PIAS1 is ubiquitously expressed. 
Localisation 
Nuclear. 
Function 
PIAS1 has been implicated in several cellular functions 
and most of them have been associated to its SUMO 
E3-ligase activity (Schimdt and Müller, 2003; Shuai 
and Liu, 2005; Rytinki et al., 2009). 
Transcriptional regulation: PIAS1 is a negative 
regulator of several transcription factors. PIAS1 was 
initially described as a negative regulator of the STAT1 
signal by blocking the DNA-binding activity of STAT1 
(Liu et al., 1998). PIAS1 SUMOylates the TP53 tumor 
suppressor, inhibiting its activity (Kahyo et al., 2001; 
Schmidt and Müller, 2002). PIAS1 SUMOylates the 
androgen receptor (AR) repressing the AR-dependent 
transcription (Nishida and Yasuda, 2002). PIAS1 also 
regulates the homeoprotein Msx1 by regulating its 
subnuclear localization and its DNA-binding 
specificity in a SUMO E3-ligase independent manner 
(Lee et al., 2006). PIAS1 SUMOylates the 
progesterone receptor (PR), and cAMP attenuates 
ligand-dependent SUMOylation of PR (Jones et al., 
2006). 
Inflammation and immunity: upon various 
inflammatory stimuli, IKKa phosphorylates PIAS1 
associating it with the promoter of NF-κB target genes 
(Liu et al., 2007).  
PIAS1 regulates the natural T regulatory cells by 
restricting their differentiation through the recruitment 
of the protein DNA-methyltransferase and CBX5 at the 
FOXP3 promoter (Liu et al., 2010). 
DNA damage: PIAS1 co-operates with PIAS4 
promoting double-strand DNA breaks repair (Galanty 
et al., 2009). 
Cancer: PIAS1 SUMOylates the promyelocytic 
leukemia (PML) gene and promotes its 
ubiquitin/proteasome-dependent degradation, inhibiting 
its tumor suppressor functions. PIAS1 also 
SUMOylates the PML-RARA oncoprotein of acute 
promyelocytic leukemia (APL); in this case, PIAS1-
dependent SUMOylation is required for the 
degradation of PML-RARA in APL cells treated with 
arsenic trioxide (Rabellino et al., 2012). 
Homology 
PIAS1 belongs to the PIAS proteins family and is 
evolutionary conserved from yeast to man. PIAS1 can 
be found in Saccharomyces cerevisiae, in plants 
(Arabidopis thaliana and Oryza sativa), 
Caernorhabditis elegans, Drosophila melanogaster, 
Danio renio, Xenopus laevis, Gallus gallus and 
mammals. All PIAS1 orthologues share a high degree 
of homology.  
The human PIAS family consists of at least 5 different 
members: PIAS1, PIAS2 (with two variants called 
PIASxα and PIASxβ), PIAS3 and PIAS4 (also known 
as PIASy). All family members share high protein 
homology, except for the C-terminus (Shuai and Liu, 
2005; Rytinki et al., 2009). 
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Schematic representation of the mutations of human PIAS1 protein found in tumor samples. Notably, most of the mutations reside 
in the PINIT domain. 
 
Mutations 
Note 
No translocations involving PIAS1 gene have been 
reported so far. 
Germinal 
No germinal mutations of PIAS1 have been reported. 
Somatic 
At least 25 different somatic mutations have been 
described in different tumor types. All the informations 
in this regard can be found at the COSMIC website. 
Implicated in 
Prostate cancer 
Note 
High expression of PIAS1 is found in malignant areas 
of prostate cancer as compared to benign areas.  
Immunohistochemistry staining positively correlates 
with positive staining for the PCNA and Ki-67 
proliferative markers suggesting a pro-proliferative role 
of PIAS1 in prostate cancer (Hoefer, 2012). 
Colon cancer 
Note 
Activated STAT3 signaling has been involved in colon 
cancer. PIAS1 is a negative regulator of the STAT 
signaling. Accordingly, PIAS1 expression is high in 
colonic non-tumor cells and adenomas, and lower in 
colon cancer cells (Coppola et al., 2009). 
Gastric cancer 
Prognosis 
One study shows that 70% of the gastric tumors 
specimens analyzed show a low level of PIAS1 
expression. Moreover, the low expression of PIAS1 
significantly correlates with tumor staging (Chen et al., 
2012). 
Non-small cell lung cancer (NSCLC) 
Note 
PIAS1-dependent SUMOylation of PML leads to its 
degradation, blocking the tumor suppression activity of 
PML. Accordingly with this observation obtained with 
in vitro experiments, a correlation between high level 
of PIAS1 protein expression and low level of PML was 
reported in NSCLC specimens.  
Furthermore, high expression of mRNA levels of 
PIAS1 in NSCLC specimens correlates with PIAS1 
gene amplification (Rabellino et al., 2012). 
Breakpoints 
Note 
None. 
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